FDA Orange Book
Is there a generic for Cycloset?
Cycloset contains bromocriptine. Orange Book status for every listed strength, the approved generic makers, and the listed patents and exclusivities.
Source: FDA Orange Book data file dated 2026-10-09. Publisher page
No. The Orange Book lists no active FDA-approved generic (ANDA) for Cycloset (bromocriptine). The Orange Book shows its last listed patent expires April 30, 2032.
Run it in Rivvi
Map Cycloset and your other top fills to their generics
Every strength in RxNorm, with brands that have no generic flagged.
Build the mapFree to start. Opens Rivvi, the AI workspace for healthcare teams.
Cycloset products in the Orange Book
| Form and route | Strength | Brand status | Brand TE | Active generics | Generic TE codes |
|---|---|---|---|---|---|
| tablet, oral | EQ 0.8MG BASE | Marketed (Rx) | None | 0 | None |
NDA 020866, held by VEROSCIENCE LLC. Active generics are ANDA products in the Orange Book prescription list with the same ingredient, dosage form, route and strength.
Cycloset patents
| Patent | Expires | Covers | Use code | NDA |
|---|---|---|---|---|
| 8877708 | June 7, 2030 | Drug product | U-1706 | 020866 |
| 9352025 | June 7, 2030 | Method of use | U-2111 | 020866 |
| 9352025 | June 7, 2030 | Method of use | U-2113 | 020866 |
| 9352025 | June 7, 2030 | Method of use | U-2117 | 020866 |
| 9895422 | June 7, 2030 | Method of use | U-2285 | 020866 |
| 9895422 | June 7, 2030 | Method of use | U-2282 | 020866 |
| 9895422 | June 7, 2030 | Method of use | U-2287 | 020866 |
| 9895422 | June 7, 2030 | Method of use | U-2116 | 020866 |
| 9895422 | June 7, 2030 | Method of use | U-2114 | 020866 |
| 9895422 | June 7, 2030 | Method of use | U-2284 | 020866 |
| 9895422 | June 7, 2030 | Method of use | U-2286 | 020866 |
| 9352025 | June 7, 2030 | Method of use | U-2114 | 020866 |
| 9352025 | June 7, 2030 | Method of use | U-2118 | 020866 |
| 9352025 | June 7, 2030 | Method of use | U-2115 | 020866 |
| 9352025 | June 7, 2030 | Method of use | U-2112 | 020866 |
| 9895422 | June 7, 2030 | Method of use | U-2281 | 020866 |
| 9895422 | June 7, 2030 | Method of use | U-2283 | 020866 |
| 9352025 | June 7, 2030 | Method of use | U-2119 | 020866 |
| 9352025 | June 7, 2030 | Method of use | U-2116 | 020866 |
| 10688155 | June 7, 2030 | Method of use | U-2898 | 020866 |
| 10688155 | June 7, 2030 | Method of use | U-2905 | 020866 |
| 10688155 | June 7, 2030 | Method of use | U-2902 | 020866 |
| 10688155 | June 7, 2030 | Method of use | U-2890 | 020866 |
| 10688155 | June 7, 2030 | Method of use | U-2914 | 020866 |
| 10688155 | June 7, 2030 | Method of use | U-2911 | 020866 |
| 10688155 | June 7, 2030 | Method of use | U-2903 | 020866 |
| 10688155 | June 7, 2030 | Method of use | U-2281 | 020866 |
| 10688155 | June 7, 2030 | Method of use | U-2901 | 020866 |
| 10688155 | June 7, 2030 | Method of use | U-2912 | 020866 |
| 10688155 | June 7, 2030 | Method of use | U-2891 | 020866 |
| 10688155 | June 7, 2030 | Method of use | U-2896 | 020866 |
| 10688155 | June 7, 2030 | Method of use | U-2893 | 020866 |
| 10688155 | June 7, 2030 | Method of use | U-2899 | 020866 |
| 10688155 | June 7, 2030 | Method of use | U-2904 | 020866 |
| 10688155 | June 7, 2030 | Method of use | U-2900 | 020866 |
| 10688155 | June 7, 2030 | Method of use | U-2906 | 020866 |
| 10688155 | June 7, 2030 | Method of use | U-2908 | 020866 |
| 10688155 | June 7, 2030 | Method of use | U-2913 | 020866 |
| 10688155 | June 7, 2030 | Method of use | U-2894 | 020866 |
| 10688155 | June 7, 2030 | Method of use | U-2910 | 020866 |
| 10688155 | June 7, 2030 | Method of use | U-2892 | 020866 |
| 10688155 | June 7, 2030 | Method of use | U-2895 | 020866 |
| 10688155 | June 7, 2030 | Method of use | U-2909 | 020866 |
| 10688155 | June 7, 2030 | Method of use | U-2897 | 020866 |
| 10688155 | June 7, 2030 | Method of use | U-2907 | 020866 |
| 10688155 | June 7, 2030 | Method of use | U-2936 | 020866 |
| 10688155 | June 7, 2030 | Method of use | U-2915 | 020866 |
| 10688155 | June 7, 2030 | Method of use | U-2935 | 020866 |
| 10688155 | June 7, 2030 | Method of use | U-2932 | 020866 |
| 10688155 | June 7, 2030 | Method of use | U-2924 | 020866 |
| 10688155 | June 7, 2030 | Method of use | U-2926 | 020866 |
| 10688155 | June 7, 2030 | Method of use | U-2931 | 020866 |
| 10688155 | June 7, 2030 | Method of use | U-2927 | 020866 |
| 10688155 | June 7, 2030 | Method of use | U-2918 | 020866 |
| 10688155 | June 7, 2030 | Method of use | U-2933 | 020866 |
| 10688155 | June 7, 2030 | Method of use | U-2916 | 020866 |
| 10688155 | June 7, 2030 | Method of use | U-2920 | 020866 |
| 10688155 | June 7, 2030 | Method of use | U-2922 | 020866 |
| 10688155 | June 7, 2030 | Method of use | U-2921 | 020866 |
| 10688155 | June 7, 2030 | Method of use | U-2919 | 020866 |
Showing 60 of 126 listed patents.
Cycloset NDC codes
Questions
Is there a generic for Cycloset?
No. The Orange Book lists no active FDA-approved generic (ANDA) for Cycloset (bromocriptine). The Orange Book shows its last listed patent expires April 30, 2032.
What is the generic name for Cycloset?
The active ingredient in Cycloset is bromocriptine, per the FDA Orange Book.
When does the Cycloset patent expire?
The last patent listed for Cycloset in the Orange Book expires April 30, 2032. A listed patent expiry date is not a generic launch date.
What does a therapeutic equivalence code mean?
In the Orange Book, codes that start with A (such as AB) mean FDA considers the product therapeutically equivalent to the reference drug. Codes that start with B mean FDA does not, at this time, consider the product therapeutically equivalent.